Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

If you're looking at Amgen and wondering whether it's time to buy, hold, or maybe even take profits, you're not alone. The ...

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish ...

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...

However, Amgen still expects decent top-line growth for the year. Its revenue guidance of $35.5 billion at the midpoint implies a revenue increase of 6.3% compared to 2024, a respectable performance ...

Amgen (AMGN) closed at $280.19 in the latest trading session, marking a -1.22% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.21%. Elsewhere, the Dow saw an ...

Amgen's performance over the past three years leaves something to be desired. But it's the future that counts, and Amgen is looking to keep growing. Its valuation is reasonable, too. Quick -- what ...

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab). AMGN stock is trending lower. View the charts here. This follows results ...